Chronically Administered Immunotherapy with Low-Dose IL-2 and IFN-α in Metastatic Renal Cell Carcinoma: A Feasible Option for Patients with a Good Prognostic Profile

Publisher： Karger

E-ISSN： 1423-0232|76|1|69-76

ISSN： 0030-2414

Source： Oncology, Vol.76, Iss.1, 2008-12, pp. : 69-76

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Five-Year Survival Results of Subcutaneous Low-Dose Immunotherapy with Interleukin-2 Alone in Metastatic Renal Cell Cancer Patients

By  

Urologia Internationalis, Vol. 64, Iss. 1, 2000-04 ,pp. : 3-8

Karger

Access to resources Recommend Favorite

Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma

By  

Oncology, Vol. 84, Iss. 2, 2012-12 ,pp. : 123-126

Karger

Access to resources Recommend Favorite

Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 919-8172, Iss. 10, 2015-10 ,pp. : 888-897

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 10, 2015-10 ,pp. : 888-897

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunotherapy of Renal Cell Carcinoma

By  

Urologia Internationalis, Vol. 63, Iss. 1, 1999-12 ,pp. : 16-21

Karger

Access to resources Recommend Favorite